Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $103.43

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $103.4286.

A number of equities analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Guggenheim upped their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Barclays assumed coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target on the stock.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Krista Davis sold 2,084 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $77.53, for a total transaction of $161,572.52. Following the transaction, the senior vice president owned 50,993 shares in the company, valued at approximately $3,953,487.29. This represents a 3.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Christopher Mutz sold 5,323 shares of the business’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $78.02, for a total transaction of $415,300.46. Following the sale, the insider directly owned 84,840 shares in the company, valued at $6,619,216.80. This trade represents a 5.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 13,459 shares of company stock worth $1,066,611. 12.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in ANI Pharmaceuticals by 9.1% in the third quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company’s stock valued at $138,000 after buying an additional 126 shares during the last quarter. Maryland State Retirement & Pension System boosted its holdings in shares of ANI Pharmaceuticals by 5.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock valued at $206,000 after acquiring an additional 134 shares during the last quarter. Illinois Municipal Retirement Fund increased its stake in shares of ANI Pharmaceuticals by 1.7% in the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock worth $782,000 after acquiring an additional 145 shares during the period. Amalgamated Bank raised its holdings in shares of ANI Pharmaceuticals by 3.1% during the third quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company’s stock worth $464,000 after purchasing an additional 154 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its holdings in shares of ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after purchasing an additional 198 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Up 1.2%

NASDAQ:ANIP opened at $76.10 on Wednesday. The company’s 50-day simple moving average is $79.99 and its 200-day simple moving average is $86.18. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.19 and a current ratio of 2.71. ANI Pharmaceuticals has a fifty-two week low of $56.71 and a fifty-two week high of $99.50. The stock has a market capitalization of $1.71 billion, a P/E ratio of 22.65 and a beta of 0.52.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.